Reduction of New Heterotopic Ossification (<scp>HO</scp>) in the <scp>Open‐Label</scp>, Phase 3 <scp>MOVE</scp> Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (<scp>FOP</scp>)
Journal of bone and mineral research